A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma orNon-Small Cell Lung Cancer

The purpose of this study is to evaluate the safety and effectiveness of an experimental drug, BDTX-1535, which is not yet approved by the United States Food and Drug Administration (FDA), in treating patients with advanced solid tumors with changes in a protein named epidermal growth factor receptor (EGFR), which may or may not help your condition during this study. However, it may help other patients in the future.

Are you Eligible? (Inclusion Criteria)

• Adults 18 years of age or older or as permitted by applicable local regulations at the time of providing informed consent. 2. Life expectancy of ≥ 3 months 3. Women of child-bearing potential must have documentation of a negative serum pregnancy test (beta-human chorionic gonadotropin [β-hCG]) prior to first dose of study treatment.